Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent.

Accept

News

Archive

Novadip Biosciences SA announces first pediatric patient with congenital pseudoarthrosis of the tibia undergoes implantation with NVD-003, an autologous tissue regeneration product, in Phase 1b/2a US/EU clinical trial Trellis Bioscience announces positive interim Phase 1 results for TRL1068, a novel native human monoclonal antibody which reduces bacterial biofilm burden in chronic prosthetic joint infections Paragraf acquires Cardea Bio to extend graphene electronics leadership VUV Analytics announces $20 million financing ProterixBio announces commercial offering of Quantitative Soluble ST2 Assay Picocom and Antevia Networks collaborate to provide new innovative 5G in-building solutions for enterprise private networks
Back To News
ProterixBio
September 28, 2017

ProterixBio

Focused on the development of molecular assessments to improve the management of chronic diseases, with an initial focus on COPD.

Cookie Policy Privacy Policy